These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 20414205)

  • 1. Monoclonal antibodies: versatile platforms for cancer immunotherapy.
    Weiner LM; Surana R; Wang S
    Nat Rev Immunol; 2010 May; 10(5):317-27. PubMed ID: 20414205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer immunotherapy--revisited.
    Lesterhuis WJ; Haanen JB; Punt CJ
    Nat Rev Drug Discov; 2011 Aug; 10(8):591-600. PubMed ID: 21804596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies for cancer immunotherapy.
    Weiner LM; Dhodapkar MV; Ferrone S
    Lancet; 2009 Mar; 373(9668):1033-40. PubMed ID: 19304016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocktails for cancer with a measure of immunotherapy.
    Ledford H
    Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
    [No Abstract]   [Full Text] [Related]  

  • 7. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.
    Melero I; Martinez-Forero I; Dubrot J; Suarez N; Palazón A; Chen L
    Clin Cancer Res; 2009 Mar; 15(5):1507-9. PubMed ID: 19240168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of membrane complement regulatory proteins in cancer immunotherapy.
    Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
    Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Tumor Antigens and Cancer Immunotherapy.
    Vigneron N
    Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.
    Peggs KS; Quezada SA; Allison JP
    Clin Exp Immunol; 2009 Jul; 157(1):9-19. PubMed ID: 19659765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy: the beginning of the end of cancer?
    Farkona S; Diamandis EP; Blasutig IM
    BMC Med; 2016 May; 14():73. PubMed ID: 27151159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches for cancer immunotherapy.
    Karlitepe A; Ozalp O; Avci CB
    Tumour Biol; 2015 Jun; 36(6):4075-8. PubMed ID: 25934338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
    Weber JS
    Melanoma Res; 2006 Oct; 16(5):379-83. PubMed ID: 17013086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances using anti-CTLA-4 for the treatment of melanoma.
    Sarnaik AA; Weber JS
    Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using antibodies in tumour immunotherapy.
    Schultes BC; Nicodemus CF
    Expert Opin Biol Ther; 2004 Aug; 4(8):1265-84. PubMed ID: 15268661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD; Saenger Y
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.